Report

Our reports provide latest industry trends, forecasts, company profiles, competitive landscape, and strategic insights.

Asset 41 2
160 1608792 circle document icon png transparent png

North America Immunodiagnostic Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product [Enzyme-Linked Immunosorbent Assays, Chemiluminescence Immunoassays (Vitamin D Assay, HIV Detection, HIV Ag/Ab Combo Assay, and Others), Radioimmunoassays, and Others], Clinical Indication [Infectious Diseases (COVID-19, Lyme, Zika, Infection Management, TORCH, Tuberculosis, Treponema, Measles & Mumps, EBV, and VZV), Hepatitis+HIV, Gastrointestinal, Metabolics[PL1] , Endocrinology (Hypertension, GROWTH, Diabetes, Thyroid, and Reproductive Endocrinology), and Others], and End User (Hospitals, Clinics, Diagnostic Laboratories, Academic & Research Institutes, and Others) [PL2] 

The North America immunodiagnostic market is expected to reach US$ 15,040.40 million in 2028 from US$ 9,188.19 million in 2021. The market is estimated to grow with a CAGR of 7.3% from 2022 to 2028.

The market growth is mainly attributed to factors such as the increasing prevalence of infectious diseases and the rising use of point-of-care immunodiagnostics. However, the inadequate reimbursement scenario hinders the market growth.

Research and development (R&D) are an essential part of pharmaceutical and biopharmaceutical businesses. R&D enables them to develop new products for various diagnostic applications with significant medical and commercial potential. Due to the increasing prevalence of infectious diseases, companies are investing and generating huge revenues, which further helps them in expansion activities. Thermo Fisher Scientific Inc. witnessed a 48% increase in sales in its Specialty Diagnostics segment (sub-segmented into clinical diagnostics, immunodiagnostics, microbiology, transplant diagnostics, and healthcare market channels) in 2020. Its segmental revenue further increased in 2021 due to higher demand, particularly for immunodiagnostics products used in the treatment of COVID-19. Additionally, in May 2021, PerkinElmer agreed to acquire Immunodiagnostic Systems (IDS), a UK-based in-vitro diagnostics company, for ~US$ 155 million. With this acquisition, PerkinElmer aims to expand its overall diagnostics business and immunodiagnostics division.
The growing R&D environment for developing innovative products opens several opportune doors for small players and start-ups. The table below displays the annual support levels for various research and disease categories based on contracts, grants, and other funding mechanisms used across the National Institutes of Health (NIH ):

Table 1. Infectious Diseases and Funding
Research/Disease Areas 2019 2020 2021 2022
Emerging Infectious Diseases US$ 2,950
US$ 4,867
US$ 5,069 US$ 4,318
Infectious Diseases US$ 6,313
US$ 8,301
US$ 8,599 US$ 8,019
Sexually Transmitted Infections US$ 354
US$ 394
US$ 404 US$ 419
Note: Current conversion rates have been considered for the representing currencies.
Source: Annual Reports and The Insight Partners Analysis.

Cisco Systems, a global technology leader, invested US$ 225 million to back its efforts for combating the COVID-19 pandemic. This initiative enabled the company to expand significantly and encouraged new players to enter the market, which are likely to aid the market’s growth in the near future.

Based on product, the immunodiagnostic market is segmented into enzyme-linked immunosorbent assays (ELISA), chemiluminescence immunoassays (CLIA), radioimmunoassays (RIA), and others. The chemiluminescence immunoassay (CLIA) is further categorized into vitamin D assay, HIV detection, HIV Ag/Ab combo assay, and others. The enzyme-linked immunosorbent assays (ELISA) segment held the largest market share in 2021. However, the chemiluminescence immunoassay (CLIA) segment is expected to grow at the highest CAGR during the forecast period. Advancements in the ELISA technique have led to the development of quantitative PCR, fluorogenic, and electrochemiluminescent reporters to generate signals. Also, the nanotechnology boom has yielded some developments in designing nanomaterial-based improved ELISA in recent years.

Based on clinical indication, the immunodiagnostic market is segmented into infectious diseases, hepatitis+HIV, gastrointestinal, metabolic diseases, endocrinology, and others. The infectious disease segment is further divided into COVID-19, Tuberculosis, Lyme, Infection Management, Zika, Treponema, TORCH, Measles & Mumps, VZV, and EBV. The infectious diseases segment held the largest share of the market in 2021 and is further anticipated to register the highest CAGR during the forecast period. Several target biomarkers and biomarker combinations are available for infectious diseases. Immunodiagnostics complements molecular assays in the study of infectious diseases. There are many immunodiagnostic tests that can be used to assist in the diagnosis of infectious, endocrine, and neoplastic diseases as well as to measure blood drug concentrations.

Based on end user, the immunodiagnostic market is segmented into hospitals, clinics, diagnostics laboratories, academic & research institutes, and others. The hospitals segment held the largest share of the market in 2021. However, the clinics segment is anticipated to register the highest CAGR during the forecast period. Immunodiagnostics tests are performed in different hospital departments, including clinical microbiology departments, pathological labs, serological labs, histopathology and hematology sections, clinical biochemistry laboratories, and hospital wards. Some of the immunodiagnostic instruments provide quick results, while in the case of complex tests, the samples are sent to the concerned laboratories. Various tests performed in hospitals include enzyme-linked immunosorbent assays (ELISA), Wstern Blot, infectious tests, and other immunological assays.

On the basis of region, the immunodiagnostic market is segmented into North America (the US, Canada, and Mexico)

ABBOTT; PerkinElmer Inc.; bioMérieux SA; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.; Siemens Healthineers AG; Thermo Fisher Scientific Inc; Danaher Corp; DiaSorin S.p.A.; and F. Hoffmann-La Roche Ltd . are the key companies operating in the North America iImmunodiagnostic immunodiagnostic market.

The World Health Organization (WHO), National Health Service (NHS), Centers for Disease Control and Prevention (CDC), American Society for Clinical Pathology, American Diabetes Association, and Biotechnology Innovation Organization (BIO) are among the major primary and secondary sources referred to while preparing the report on the North America immunodiagnostics market.

TABLE OF CONTENTS

1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Immunodiagnostics Market – By Product
1.3.2 North America Immunodiagnostics Market – By Clinical Indication
1.3.3 North America Immunodiagnostics Market – By End User
1.3.4 North America Immunodiagnostics Market– By Country
2. North America Immunodiagnostics Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Immunodiagnostics Market– Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America – PEST Analysis
4.3 Experts Opinion
5. Immunodiagnostics Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Prevalence of Infectious Diseases
5.1.2 Increasing Use of Point-of-Care Immunodiagnostics
5.2 Market Restraints
5.2.1 Inadequate Reimbursement Scenario
5.3 Market Opportunities
5.3.1 Rising Focus On R&D Investment and Expansion by Key Players
5.4 Future Trends
5.4.1 Technological Advancements in The Field of Immunodiagnostics
5.5 Impact Analysis
6. Immunodiagnostics Market– North America Analysis
6.1 North America Immunodiagnostics Market Revenue Forecast and Analysis
6.1.1 Company Analysis
6.2 Comparative Company Analysis
6.2.1 Market Share Analysis (2021)
6.2.2 Growth Strategy Analysis
6.2.3 Market Positioning of Key Players in Immunodiagnostics Market
6.2.3.1 Abbott
6.2.3.2 F. Hoffmann-La Roche Ltd
7. Immunodiagnostics Market Analysis and Forecasts To 2028 – By Product
7.1 Overview
7.2 North America Immunodiagnostics Market, By Product 2021 & 2028 (%)
7.3 Enzyme-Linked Immunosorbent Assays (ELISA)
7.3.1 Overview
7.3.2 Enzyme-Linked Immunosorbent Assays (ELISA) Market Revenue and Forecast to 2028 (US$ Million)
7.4 Chemiluminescence Immunoassays (CLIA)
7.4.1 Overview
7.4.2 Chemiluminescence Immunoassays (CLIA) Market Revenue and Forecast to 2028 (US$ Million)
7.4.3 Vitamin D Assay
7.4.3.1 Overview
7.4.3.2 Vitamin D Assay Market Revenue and Forecast to 2028 (US$ Million)
7.4.4 HIV Detection
7.4.4.1 Overview
7.4.4.2 HIV Detection Market Revenue and Forecast to 2028 (US$ Million)
7.4.5 HIV Ag/Ab Combo Assay
7.4.5.1 Overview
7.4.5.2 HIV Ag/Ab Combo Assay Market Revenue and Forecast to 2028 (US$ Million)
7.4.6 Others
7.4.6.1 Overview
7.4.6.2 Others Market Revenue and Forecast to 2028 (US$ Million)
7.5 Radioimmunoassays (RIA)
7.5.1 Overview
7.5.2 Radioimmunoassays (RIA) Market Revenue and Forecast to 2028 (US$ Million)
7.6 Others
7.6.1 Overview
7.6.2 Others Market Revenue and Forecast to 2028 (US$ Million)
8. Immunodiagnostics Market Analysis and Forecasts To 2028 – By Clinical Indication
8.1 Overview
8.2 North America Immunodiagnostics Market, By Clinical Indication 2021 & 2028 (%)
8.3 Infectious Diseases
8.3.1 Overview
8.3.2 Infectious Diseases Market Revenue and Forecast to 2028 (US$ Million)
8.3.3 COVID-19
8.3.3.1 Overview
8.3.3.2 COVID-19 Market Revenue and Forecast to 2028 (US$ Million)
8.3.4 Lyme
8.3.4.1 Overview
8.3.4.2 Lyme Market Revenue and Forecast to 2028 (US$ Million)
8.3.5 Zika
8.3.5.1 Overview
8.3.5.2 Zika Market Revenue and Forecast to 2028 (US$ Million)
8.3.6 Infection Management
8.3.6.1 Overview
8.3.6.2 Infection Management Market Revenue and Forecast to 2028 (US$ Million)
8.3.7 TORCH
8.3.7.1 Overview
8.3.7.2 TORCH Market Revenue and Forecast to 2028 (US$ Million)
8.3.8 Tuberculosis
8.3.8.1 Overview
8.3.8.2 Tuberculosis Market Revenue and Forecast to 2028 (US$ Million)
8.3.9 Treponema
8.3.9.1 Overview
8.3.9.2 Treponema Market Revenue and Forecast to 2028 (US$ Million)
8.3.10 Measles and Mumps
8.3.10.1 Overview
8.3.10.2 Measles and Mumps Market Revenue and Forecast to 2028 (US$ Million)
8.3.11 EBV
8.3.11.1 Overview
8.3.11.2 EBV Market Revenue and Forecast to 2028 (US$ Million)
8.3.12 VZV
8.3.12.1 Overview
8.3.12.2 VZV Market Revenue and Forecast to 2028 (US$ Million)
8.4 Hepatitis+HIV
8.4.1 Overview
8.4.2 Hepatitis+HIV Market Revenue and Forecast to 2028 (US$ Million)
8.5 Gastrointestinal
8.5.1 Overview
8.5.2 Gastrointestinal Market Revenue and Forecast to 2028 (US$ Million)
8.6 Metabolics
8.6.1 Overview
8.6.2 Metabolics Market Revenue and Forecast to 2028 (US$ Million)
8.7 Endocrinology
8.7.1 Overview
8.7.2 Endocrinology Market Revenue and Forecast to 2028 (US$ Million)
8.7.3 Hypertension
8.7.3.1 Overview
8.7.3.2 Hypertension Market Revenue and Forecast to 2028 (US$ Million)
8.7.4 GROWTH
8.7.4.1 Overview
8.7.4.2 GROWTH Market Revenue and Forecast to 2028 (US$ Million)
8.7.5 Diabetes
8.7.5.1 Overview
8.7.5.2 Diabetes Market Revenue and Forecast to 2028 (US$ Million)
8.7.6 Thyroid
8.7.6.1 Overview
8.7.6.2 Thyroid Market Revenue and Forecast to 2028 (US$ Million)
8.7.7 Reproductive Endocrinology
8.7.7.1 Overview
8.7.7.2 Reproductive Endocrinology Market Revenue and Forecast to 2028 (US$ Million)
9. Immunodiagnostics Market Analysis and Forecasts To 2028 – By End User
9.1 Overview
9.2 North America Immunodiagnostics Market, By End User 2021 & 2028 (%)
9.3 Hospitals
9.3.1 Overview
9.3.2 Hospitals Market Revenue and Forecast to 2028 (US$ Million)
9.4 Clinics
9.4.1 Overview
9.4.2 Clinics Market Revenue and Forecast to 2028 (US$ Million)
9.5 Diagnostics Laboratories
9.5.1 Overview
9.5.2 Diagnostic Laboratories Market Revenue and Forecast to 2028 (US$ Million)
9.6 Academic and Research Institutes
9.6.1 Overview
9.6.2 Academic and Research Institutes Market Revenue and Forecast to 2028 (US$ Million)
9.7 Others
9.7.1 Overview
9.7.2 Others Market Revenue and Forecast to 2028 (US$ Million)
10. North America Immunodiagnostics Market – Country Analysis
10.1 North America: Immunodiagnostics Market
10.1.1 Overview
10.1.2 North America: Immunodiagnostics Market – Revenue and Forecast to 2028 (USD Million)
10.1.3 North America Immunodiagnostics Market, by Product – Revenue and Forecast to 2028 (USD Million)
10.1.3.1 North America Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2028 (USD Million)
10.1.4 North America Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2028 (USD Million)
10.1.4.1 North America Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2028 (USD Million)
10.1.4.2 North America Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2028 (USD Million)
10.1.5 North America Immunodiagnostics Market, by End User – Revenue and Forecast to 2028 (USD Million)
10.1.6 North America: Immunodiagnostics Market, by Country, 2021 & 2028 (%)
10.1.6.1 US: Immunodiagnostics Market – Revenue and Forecast to 2028 (USD Million)
10.1.6.1.1 US: Immunodiagnostics Market – Revenue and Forecast to 2028 (USD Million)
10.1.6.1.2 US Immunodiagnostics Market, by Product – Revenue and Forecast to 2028 (USD Million)
10.1.6.1.2.1 US Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2028 (USD Million)
10.1.6.1.3 US Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2028 (USD Million)
10.1.6.1.3.1 US Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2028 (USD Million)
10.1.6.1.3.2 US Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2028 (USD Million)
10.1.6.1.4 US: Immunodiagnostics Market, by End User – Revenue and Forecast to 2028 (USD Million)
10.1.6.2 Canada: Immunodiagnostics Market – Revenue and Forecast to 2028 (USD Million)
10.1.6.2.1 Canada: Immunodiagnostics Market – Revenue and Forecast to 2028 (USD Million)
10.1.6.2.2 Canada Immunodiagnostics Market, by Product – Revenue and Forecast to 2028 (USD Million)
10.1.6.2.2.1 Canada Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA) – Revenue and Forecast to 2028 (USD Million)
10.1.6.2.3 Canada Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2028 (USD Million)
10.1.6.2.3.1 Canada Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2028 (USD Million)
10.1.6.2.3.2 Canada Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2028 (USD Million)
10.1.6.2.4 Canada Immunodiagnostics Market, by End User – Revenue and Forecast to 2028 (USD Million)
10.1.6.3 Mexico: Immunodiagnostics Market – Revenue and Forecast to 2028 (USD Million)
10.1.6.3.1 Mexico: Immunodiagnostics Market – Revenue and Forecast to 2028 (USD Million)
10.1.6.3.2 Mexico Immunodiagnostics Market, by Product – Revenue and Forecast to 2028 (USD Million)
10.1.6.3.2.1 Mexico Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA) – Revenue and Forecast to 2028 (USD Million)
10.1.6.3.3 Mexico Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2028 (USD Million)
10.1.6.3.3.1 Mexico Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2028 (USD Million)
10.1.6.3.3.2 Mexico Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2028 (USD Million)
10.1.6.3.4 Mexico Immunodiagnostics Market, by End User – Revenue and Forecast to 2028 (USD Million)
11. North America: Impact Assessment of COVID-19 Pandemic
12. Immunodiagnostics Market –Industry Landscape
12.1 Overview
12.2 Growth Strategies in the Immunodiagnostics Market (%)
12.3 Organic Developments
12.3.1 Overview
12.4 Inorganic Developments
12.4.1 Overview
13. Company Profiles
13.1 Abbott Laboratories
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 F. Hoffmann-La Roche Ltd
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 DiaSorin S.p.A.
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Danaher Corp
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Thermo Fisher Scientific Inc
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Siemens Healthineers AG
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Financial Overview
13.6.4 SWOT Analysis
13.6.5 Key Developments
13.7 PerkinElmer Inc.
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 bioMerieux SA
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms

LIST OF TABLES

Table 1. Infectious Diseases and Funding
Table 2. North America Immunodiagnostics Market, by Product – Revenue and Forecast to 2028 (USD Million)
Table 3. North America Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2028 (USD Million)
Table 4. North America Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2028 (USD Million)
Table 5. North America Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2028 (USD Million)
Table 6. North America Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2028 (USD Million)
Table 7. North America Immunodiagnostics Market, by End User- Revenue and Forecast to 2028 (USD Million)
Table 8. US Immunodiagnostics Market, by Product – Revenue and Forecast to 2028 (USD Million)
Table 9. US Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2028 (USD Million)
Table 10. US Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2028 (USD Million)
Table 11. US Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2028 (USD Million)
Table 12. US Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2028 (USD Million)
Table 13. US Immunodiagnostics Market, by End User- Revenue and Forecast to 2028 (USD Million)
Table 14. Canada Immunodiagnostics Market, by Product -Revenue and Forecast to 2028 (USD Million)
Table 15. Canada Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA) -Revenue and Forecast to 2028 (USD Million)
Table 16. Canada Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2028 (USD Million)
Table 17. Canada Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2028 (USD Million)
Table 18. Canada Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2028 (USD Million)
Table 19. Canada Immunodiagnostics Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 20. Mexico Immunodiagnostics Market, by Product -Revenue and Forecast to 2028 (USD Million)
Table 21. Mexico Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA) -Revenue and Forecast to 2028 (USD Million)
Table 22. Mexico Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2028 (USD Million)
Table 23. Mexico Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2028 (USD Million)
Table 24. Mexico Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2028 (USD Million)
Table 25. Mexico Immunodiagnostics Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 26. Organic Developments in the Immunodiagnostics Market
Table 27. Inorganic Developments in the Immunodiagnostics Market
Table 28. Glossary of Terms, Immunodiagnostic Market

LIST OF FIGURES

Figure 1. Immunodiagnostics Market Segmentation
Figure 2. Immunodiagnostics Market Segmentation, By Country
Figure 3. North America Immunodiagnostics Market Overview
Figure 4. Enzyme-Linked Immunosorbent Assays (ELISA) Held the Largest Share of the Product Segment in Immunodiagnostics Market
Figure 5. US Held Largest Market Share During Forecast Period
Figure 6. North America Immunodiagnostics Market– Leading Country Markets (US$ Million)
Figure 7. North America Immunodiagnostics Market, Industry Landscape
Figure 8. North America PEST Analysis
Figure 9. Immunodiagnostics Market: Impact Analysis of Drivers and Restraints
Figure 10. North America Immunodiagnostics Market – Revenue Forecast and Analysis – 2020- 2028
Figure 11. Market Share Analysis of Key Players in Immunodiagnostics Market
Figure 12. North America Immunodiagnostics Market – Comparative Company Analysis
Figure 13. North America Immunodiagnostics Market – Growth Strategy Analysis
Figure 14. North America Immunodiagnostics Market, by Product 2021 & 2028 (%)
Figure 15. Enzyme-Linked Immunosorbent Assays (ELISA) Market Revenue and Forecasts to 2028 (US$ Million)
Figure 16. Chemiluminescence Immunoassays (CLIA) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 17. Vitamin D Assay Market Revenue and Forecasts To 2028 (US$ Million)
Figure 18. HIV Detection Market Revenue and Forecasts To 2028 (US$ Million)
Figure 19. HIV Ag/Ab Combo Assay Market Revenue and Forecasts To 2028 (US$ Million)
Figure 20. Others Market Revenue and Forecasts To 2028 (US$ Million)
Figure 21. Radioimmunoassays (RIA) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 22. Others Market Revenue and Forecasts To 2028 (US$ Million)
Figure 23. North America Immunodiagnostics Market, by Clinical Indication 2021 & 2028 (%)
Figure 24. Infectious Diseases Market Revenue and Forecasts to 2028 (US$ Million)
Figure 25. COVID-19 Market Revenue and Forecasts To 2028 (US$ Million)
Figure 26. Lyme Market Revenue and Forecasts To 2028 (US$ Million)
Figure 27. Zika Market Revenue and Forecasts To 2028 (US$ Million)
Figure 28. Infection Management Market Revenue and Forecasts To 2028 (US$ Million)
Figure 29. TORCH Market Revenue and Forecasts To 2028 (US$ Million)
Figure 30. 2.3.5 Tuberculosis Market Revenue and Forecasts To 2028 (US$ Million)
Figure 31. Treponema Market Revenue and Forecasts To 2028 (US$ Million)
Figure 32. Measles and Mumps Market Revenue and Forecasts To 2028 (US$ Million)
Figure 33. EBV Market Revenue and Forecasts To 2028 (US$ Million)
Figure 34. VZV Market Revenue and Forecasts To 2028 (US$ Million)
Figure 35. Hepatitis+HIV Market Revenue and Forecasts to 2028 (US$ Million)
Figure 36. Gastrointestinal Market Revenue and Forecasts to 2028 (US$ Million)
Figure 37. Metabolics Market Revenue and Forecasts to 2028 (US$ Million)
Figure 38. Endocrinology Market Revenue and Forecasts to 2028 (US$ Million)
Figure 39. Hypertension Market Revenue and Forecasts To 2028 (US$ Million)
Figure 40. GROWTH Market Revenue and Forecasts To 2028 (US$ Million)
Figure 41. Diabetes Market Revenue and Forecasts To 2028 (US$ Million)
Figure 42. Throid Market Revenue and Forecasts To 2028 (US$ Million)
Figure 43. Reproductive Endocrinology Market Revenue and Forecasts To 2028 (US$ Million)
Figure 44. North America Immunodiagnostics Market, by End User 2021 & 2028 (%)
Figure 45. Hospitals Market Revenue and Forecasts to 2028 (US$ Million)
Figure 46. Clinics Market Revenue and Forecasts to 2028 (US$ Million)
Figure 47. Diagnostics Laboratories Market Revenue and Forecasts to 2028 (US$ Million)
Figure 48. Research & Academic Institutes Market Revenue and Forecasts to 2028 (US$ Million)
Figure 49. Others Market Revenue and Forecasts to 2028 (US$ Million)
Figure 50. North America: Immunodiagnostics Market, by Key Country – Revenue (2021) (USD Million)
Figure 51. North America Immunodiagnostics Market Revenue and Forecast to 2028 (USD Million)
Figure 52. North America: Immunodiagnostics Market, by Country, 2021 & 2028 (%)
Figure 53. US: Immunodiagnostics Market – Revenue and Forecast to 2028 (USD Million)
Figure 54. Canada: Immunodiagnostics Market – Revenue and Forecast to 2028 (USD Million)
Figure 55. Mexico: Immunodiagnostics Market – Revenue and Forecast to 2028 (USD Million)
Figure 56. Impact of COVID-19 Pandemic on North American Countries Markets
Figure 57. Growth Strategies in the Immunodiagnostics Market (%)

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America immunodiagnostic market.
• Highlights key business priorities in order to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in the immunodiagnostic market in North America, thereby allowing players across the value chain to develop effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth regional market trends and outlook coupled with the factors driving the market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

The List of Companies – North America Immunodiagnostic Market

1. Abbott Laboratories
2. F. Hoffmann-La Roche Ltd
3. DiaSorin S.p.A.
4. Danaher Corp
5. Thermo Fisher Scientific Inc
6. Siemens Healthineers AG
7. PerkinElmer Inc.
8. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
9. bioMerieux SA

Pricing

$3,000.00$5,000.00

Have a Query?

Have a Question?

Related Reports

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

GET FREE SAMPLE PDF

× Enquire Now